Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Clinical Immunology
Erschienen in: Journal of Clinical Immunology 5/2013

01.07.2013 | Key Review Article

Biology of Human Pentraxin 3 (PTX3) in Acute and Chronic Kidney Disease

verfasst von: Marijn M. Speeckaert, Reinhart Speeckaert, Juan J. Carrero, Raymond Vanholder, Joris R. Delanghe

Erschienen in: Journal of Clinical Immunology | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

The pentraxin superfamily consists of highly conserved multimeric pattern recognition proteins, which are components of the humoral arm of innate immunity. Besides the classical pentraxins (C-reactive protein and serum amyloid P component), pentraxin 3 (PTX3) is a prototypic long pentraxin. In response to primary inflammatory signals, this multifunctional acute phase protein is produced by a variety of cell types. Recently, several clinical studies have demonstrated that PTX3 is significantly associated with kidney dysfunction and disease activity or severity in various inflammatory, cardiovascular and autoimmune diseases. In this paper, we will review the general characteristics of PTX3 focusing in particular on its fundamental biological functions in the course of acute and chronic kidney diseases.
Literatur
1.
Imai N, Nishi S, Yoshita K, et al. Pentraxin-3 expression in acute renal allograft rejection. Clin Transplant. 2012;26:25–31.PubMedCrossRef
2.
Bottazzi B, Garlanda C, Cotena A, et al. The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity. Immunol Rev. 2009;227:9–18.PubMedCrossRef
3.
Bottazzi B, Doni A, Garlanda C, et al. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol. 2010;28:157–83.PubMedCrossRef
4.
Jaillon S, Peri G, Delneste Y, et al. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med. 2007;204:793–804.PubMedCrossRef
5.
Menegazzi R, Decleva E, Dri P. Killing by neutrophil extracellular traps: fact or folklore? Blood. 2012;19:1214–6.CrossRef
6.
Doni A, Michela M, Bottazzi B, et al. Regulation of PTX3, a key component of humoral innate immunity in human dendritic cells: stimulation by IL-10 and inhibition by IFN-gamma. J Leukoc Biol. 2006;79:797–802.PubMedCrossRef
7.
Inforzato A, Jaillon S, Moalli F, et al. The long pentraxin PTX3 at the crossroads between innate immunity and tissue remodelling. Tissue Antigens. 2011;77:271–82.PubMedCrossRef
8.
He X, Han B, Liu M. Long pentraxin 3 in pulmonary infection and acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2007;292:L1039–49.PubMedCrossRef
9.
Deban L, Jaillon S, Garlanda C, et al. Pentraxins in innate immunity: lessons from PTX3. Cell Tissue Res. 2011;343:237–49.PubMedCrossRef
10.
Soares AC, Souza DG, Pinho V, et al. Dual function of the long pentraxin PTX3 in resistance against pulmonary infection with Klebsiella pneumoniae in transgenic mice. Microbes Infect. 2006;8:1321–9.PubMedCrossRef
11.
Kunes P, Holubcova Z, Kolackova M, et al. Pentraxin 3(PTX 3): an endogenous modulator of the inflammatory response. Mediators Inflamm. 2012;2012:920517.PubMedCrossRef
12.
He X, Han B, Bai X, et al. PTX3 as a potential biomarker of acute lung injury: supporting evidence from animal experimentation. Intensive Care Med. 2010;36:356–64.PubMedCrossRef
13.
van Rossum AP, Pas HH, Fazzini F, et al. Abundance of the long pentraxin PTX3 at sites of leukocytoclastic lesions in patients with small-vessel vasculitis. Arthritis Rheum. 2006;54:986–91.PubMedCrossRef
14.
Hamad RR, Eriksson MJ, Berg E, et al. Impaired endothelial function and elevated levels of pentraxin 3 in early-onset preeclampsia. Acta Obstet Gynecol Scand. 2012;91:50–6.PubMedCrossRef
15.
Garlanda C, Bottazzi B, Bastone A, et al. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337–66.PubMedCrossRef
16.
Garlanda C, Maina V, Cotena A, et al. The soluble pattern recognition receptor pentraxin-3 in innate immunity, inflammation and fertility. J Reprod Immunol. 2009;83:128–33.PubMedCrossRef
17.
Inforzato A, Rivieccio V, Morreale AP, et al. Structural characterization of PTX3 disulfide bond network and its multimeric status in cumulus matrix organization. J Biol Chem. 2008;283:10147–61.PubMedCrossRef
18.
Bottazzi B, Vouret-Craviari V, Bastone A, et al. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem. 1997;272:32817–23.PubMedCrossRef
19.
Introna M, Alles VV, Castellano M, et al. Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood. 1996;87:1862–72.PubMed
20.
Scarchilli L, Camaioni A, Bottazzi B, et al. PTX3 interacts with inter-alphatrypsin inhibitor: implications for hyaluronan organization and cumulus oophorus expansion. J Biol Chem. 2007;282:30161–70.PubMedCrossRef
21.
Moalli F, Jaillon S, Inforzato A, et al. Pathogen recognition by the long pentraxin PTX3. J Biomed Biotechnol. 2011;2011:830421.PubMedCrossRef
22.
Meier P. Plasma sTWEAK and PTX3. New determinant tools of cardiovascular outcome also in patients with CKD. Clin J Am Soc Nephrol. 2011;6:697–9.PubMedCrossRef
23.
Olesen R, Wejse C, Velez DR, et al. DC-SIGN (CD209), pentraxin 3 and vitamin D receptor gene variants associate with pulmonary tuberculosis risk in West Africans. Genes Immun. 2007;8:456–67.PubMedCrossRef
24.
Chiarini M, Sabelli C, Melotti P, et al. PTX3 genetic variations affect the risk of Pseudomonas aeruginosa airway colonization in cystic fibrosis patients. Genes Immun. 2010;11:665–70.PubMedCrossRef
25.
May L, Kuningas M, van Bodegom D, et al. Genetic variation in pentraxin (PTX) 3 gene associates with PTX3 production and fertility in women. Biol Reprod. 2010;82:299–304.PubMedCrossRef
26.
Nauta AJ, Bottazzi B, Mantovani A, et al. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol. 2003;33:465–73.PubMedCrossRef
27.
Ma YJ, Doni A, Hummelshøj T, et al. Synergy between ficolin-2 and pentraxin 3 boosts innate immune recognition and complement deposition. J Biol Chem. 2009;284:28263–75.PubMedCrossRef
28.
Ma YJ, Doni A, Skjoedt MO, et al. Heterocomplexes of mannose-binding lectin and the pentraxins PTX3 or serum amyloid P component trigger cross-activation of the complement system. J Biol Chem. 2011;286:3405–17.PubMedCrossRef
29.
Gout E, Moriscot C, Doni A, et al. M-ficolin interacts with the long pentraxin PTX3: a novel case of cross-talk between soluble pattern-recognition molecules. J Immunol. 2011;186:5815–22.PubMedCrossRef
30.
Braunschweig A, Józsi M. Human pentraxin 3 binds to the complement regulator c4b-binding protein. PLoS One. 2011;6:e23991.PubMedCrossRef
31.
Deban L, Jarva H, Lehtinen MJ, et al. Binding of the long pentraxin PTX3 to factor H: interacting domains and function in the regulation of complement activation. J Immunol. 2008;181:8433–40.PubMed
32.
Kopp A, Strobel S, Tortajada A, et al. Atypical hemolytic uremic syndrome associated variants and autoantibodies impair binding of factor h and factor h-related protein 1 to pentraxin 3. J Immunol. 2012;189:1858–67.PubMedCrossRef
33.
Leali D, Alessi P, Coltrini D, et al. Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors. Mol Cancer Ther. 2011;10:1600–10.PubMedCrossRef
34.
Deban L, Russo RC, Sironi M, et al. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol. 2010;11:328–42.PubMedCrossRef
35.
Chavakis T. Leucocyte recruitment in inflammation and novel endogenous negative regulators thereof. Eur J Clin Invest. 2012;42:686–91.PubMedCrossRef
36.
Manfredi AA, Rovere-Querini P, Bottazzi B, et al. Pentraxins, humoral innate immunity and tissue injury. Curr Opin Immunol. 2008;20:538–44.PubMedCrossRef
37.
Dubin R, Shlipak M, Li Y, et al. Racial differences in the association of pentraxin-3 with kidney dysfunction: the Multi-Ethnic Study of Atherosclerosis. Nephrol Dial Transplant. 2011;26:1903–8.PubMedCrossRef
38.
Chen J, Matzuk MM, Zhou XJ, et al. Endothelial pentraxin 3 contributes to murine ischemic acute kidney injury. Kidney Int. 2012;82:1195–207.PubMedCrossRef
39.
Wu H, Chen G, Wyburn KR, et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest. 2007;117:2847–59.PubMedCrossRef
40.
Eltzschig HK, Eckle T. Ischemia and reperfusion—from mechanism to translation. Nat Med. 2011;17:1391–401.PubMedCrossRef
41.
Chen J, John R, Richardson JA, et al. Toll-like receptor 4 regulates early endothelial activation during ischemic acute kidney injury. Kidney Int. 2011;79:288–99.PubMedCrossRef
42.
Salio M, Chimenti S, De Angelis N, et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2008;117:1055–64.PubMedCrossRef
43.
Lech M, Römmele C, Gröbmayr R, et al. Endogenous and exogenous pentraxin-3 limits postischemic acute and chronic kidney injury. Kidney Int. 2013. doi:10.​1038/​ki.​2012.​463.
44.
Anders HJ, Ryu M. Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int. 2011;80:915–25.PubMedCrossRef
45.
Muller B, Peri G, Doni A, et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med. 2001;29:1404–7.PubMedCrossRef
46.
Huttunen R, Hurme M, Aittoniemi J, et al. High plasma level of long pentraxin 3 (PTX3) is associated with fatal disease in bacteremic patients: a prospective cohort study. PLoS One. 2011;6:e17653.PubMedCrossRef
47.
Daigo K, Yamaguchi N, Kawamura T, et al. The proteomic profile of circulating pentraxin 3 (PTX3) complex in sepsis demonstrates the interaction with azurocidin 1 and other components of neutrophil extracellular traps. Mol Cell Proteomics. 2012;11:M111.015073.PubMedCrossRef
48.
Mauri T, Bellani G, Patroniti N, et al. Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. Intensive Care Med. 2010;36:621–9.PubMedCrossRef
49.
Mantovani A, Garlanda C, Doni A, et al. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol. 2008;28:1–13.PubMedCrossRef
50.
Du Clos TW, Mold C. Pentraxins (CRP, SAP) in the process of complement activation and clearance of apoptotic bodies through Fcγ receptors. Curr Opin Organ Transplant. 2010. doi:10.​1097/​MOT.​0b013e32834253c7​.
51.
Sagedal S, Nordal KP, Hartmann A, et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation. 2000;70:1166–74.PubMedCrossRef
52.
Sagedal S, Hartmann A, Rollag H. The impact of early cytomegalovirus infection and disease in renal transplant recipients. Clin Microbiol Infect. 2005;11:518–30.PubMedCrossRef
53.
Dengler TJ, Raftery MJ, Werle M, et al. Cytomegalovirus infection of vascular cells induces expression of pro-inflammatory adhesion molecules by paracrine action of secreted interleukin-1beta. Transplantation. 2000;69:160–1168.CrossRef
54.
Rollag H, Asberg A, Ueland T, et al. Treatment of cytomegalovirus disease in solid organ transplant recipients: markers of inflammation as predictors of outcome. Transplantation. 2012;94:1060–5.PubMedCrossRef
55.
Józsi M, Oppermann M, Lambris JD, et al. The C-terminus of complement factor H is essential for host cell protection. Mol Immunol. 2007;44:2697–706.PubMedCrossRef
56.
57.
Ferreira VP, Herbert AP, Cortés C, et al. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol. 2009;182:7009–18.PubMedCrossRef
58.
Tong M, Carrero JJ, Qureshi AR, et al. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, proteinenergy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol. 2007;2:889–97.PubMedCrossRef
59.
Dubin R, Li Y, Ix JH, et al. Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study. Am Heart J. 2012;163:274–9.PubMedCrossRef
60.
Yilmaz MI, Sonmez A, Ortiz A, et al. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol. 2011;6:785–92.PubMedCrossRef
61.
Savchenko A, Imamura M, Ohashi R, et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol. 2008;215:48–55.PubMedCrossRef
62.
Bassi N, Zampieri S, Ghirardello A, et al. Pentraxins, anti-pentraxin antibodies, and atherosclerosis. Clin Rev Allergy Immunol. 2009;37:36–43.PubMedCrossRef
63.
Suliman ME, Yilmaz MI, Carrero JJ, et al. Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:976–85.PubMedCrossRef
64.
Yilmaz MI, Carrero JJ, Martín-Ventura JL, et al. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol. 2010;5:1174–81.PubMedCrossRef
65.
Norata GD, Marchesi P, Pulakazhi Venu VK, et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation. 2009;120:699–708.PubMedCrossRef
66.
Norata GD, Garlanda C, Catapano AL. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med. 2010;20:35–40.PubMedCrossRef
67.
Kanbay M, Ikizek M, Solak Y, et al. Uric acid and pentraxin-3 levels are independently associated with coronary artery disease risk in patients with stage 2 and 3 kidney disease. Am J Nephrol. 2011;33:325–31.PubMedCrossRef
68.
Knoflach M, Kiechl S, Mantovani A, et al. Pentraxin-3 as a marker of advanced atherosclerosis results from the Bruneck, ARMY and ARFY Studies. PLoS One. 2012;7:e31474.PubMedCrossRef
69.
Turkmen K, Tonbul HZ, Toker A, et al. The relationship between oxidative stress, inflammation, and atherosclerosis in renal transplant and end-stage renal disease patients. Ren Fail. 2012;34:1229–37.PubMedCrossRef
70.
Argani H, Ghorbanihaghjo A, Panahi G, et al. Serum Fetuin-A and Pentraxin3 in hemodialysis and renal transplant patients. Clin Biochem. 2012;45:775–9.PubMedCrossRef
71.
Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415–45.PubMedCrossRef
72.
Ogawa T, Kawano Y, Imamura T, et al. Reciprocal contribution of pentraxin 3 and C-reactive protein to obesity and metabolic syndrome. Obesity (Silver Spring). 2010;18:1871–4.PubMedCrossRef
73.
Suliman ME, Qureshi AR, Carrero JJ, et al. The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality. QJM. 2008;101:397–405.PubMedCrossRef
74.
Miyamoto T, Rashid Qureshi A, Heimbürger O, et al. Carrero, Inverse relationship between the inflammatory marker pentraxin-3, fat body mass, and abdominal obesity in end-stage renal disease. Clin J Am Soc Nephrol. 2011;6:2785–91.PubMedCrossRef
75.
Osorio-Conles O, Guitart M, Chacón MR, et al. Plasma PTX3 protein levels inversely correlate with insulin secretion and obesity, whereas visceral adipose tissue PTX3 gene expression is increased in obesity. Am J Physiol Endocrinol Metab. 2011;301:E1254–61.PubMedCrossRef
76.
Tesauro M, Canale MP, Rodia G, et al. Metabolic syndrome, chronic kidney, and cardiovascular diseases: role of adipokines. Cardiol Res Pract. 2011;2011:653182.PubMed
77.
Napoleone E, Di Santo A, Bastone A, et al. Long pentraxin PTX3 upregulates tissue factor expression in human endothelial cells: a novel link between vascular inflammation and clotting activation. Arterioscler Thromb Vasc Biol. 2002;22:782–7.PubMedCrossRef
78.
Bassi N, Ghirardello A, Blank M, et al. IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus. Ann Rheum Dis. 2010;69:1704–10.PubMedCrossRef
79.
Doria A, Gatto M. Nephritogenic-antinephritogenic antibody network in lupus glomerulonephritis. Lupus. 2012;21:1492–6.PubMedCrossRef
80.
Augusto JF, Onno C, Blanchard S, et al. Detection of anti-PTX3 autoantibodies in systemic lupus erythematosus. Rheumatology (Oxford). 2009;48:442–4.PubMedCrossRef
81.
Rovere P, Peri G, Fazzini F, et al. The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood. 2000;96:4300–6.PubMed
82.
Lech M, Römmele C, Kulkarni OP, et al. Lack of the long pentraxin PTX3 promotes autoimmune lung disease but not glomerulonephritis in murine systemic lupus erythematosus. PLoS One. 2011;6:e20118.PubMedCrossRef
83.
84.
Fazzini F, Peri G, Doni A, et al. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum. 2011;44:2841–50.CrossRef
85.
Maugeri N, Rovere-Querini P, Baldini M, et al. Translational mini-review series on immunology of vascular disease: mechanisms of vascular inflammation and remodelling in systemic vasculitis. Clin Exp Immunol. 2009;156:395–404.PubMedCrossRef
86.
LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am. 1996;22:675–94.PubMedCrossRef
87.
Giusti G, Fibbi G, Margheri F, et al. A model of antiangiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Res Ther. 2006;8:R115.PubMedCrossRef
88.
Margheri F, Serratì S, Lapucci A, et al. Modulation of the angiogenic phenotype of normal and systemic sclerosis endothelial cells by gain-loss of function of pentraxin 3 and matrix metalloproteinase 12. Arthritis Rheum. 2010;62:2488–98.PubMedCrossRef
89.
Boehme M, Kaehne F, Kuehne A, et al. Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease. Nephrol Dial Transplant. 2007;22:2224–9.PubMedCrossRef
90.
Lavín-Gómez BA, Palomar-Fontanet R, Gago-Fraile M, et al. Inflammation markers, chronic kidney disease, and renal replacement therapy. Adv Perit Dial. 2011;27:33–7.PubMed
91.
92.
Xu Y, Ding X, Zou J, et al. Plasma pentraxin 3 is associated with cardiovascular disease in hemodialysis patients. Ren Fail. 2011;33:998–1004.PubMedCrossRef
93.
Oldani S, Finazzi S, Bottazzi B, et al. Plasma pentraxin-3 as a marker of bioincompatibility in hemodialysis patients. J Nephrol. 2012;25:120–6.PubMedCrossRef
94.
95.
Bussolati B, Peri G, Salvidio G, et al. The long entraxin PTX3 is synthesized in IgA glomerulonephritis and activates mesangial cells. J Immunol. 2003;170:1466–72.PubMed
96.
Lech M, Rommele C, Anders HJ. Pentraxins in nephrology: C-reactive protein, serum amyloid P and pentraxin-3. Nephrol Dial Transplant. 2012. doi:10.​1093/​ndt/​gfs448.
97.
Hisano S, Matsushita M, Fujita T, et al. Activation of the lectin complement pathway in Henoch-Schönlein purpura nephritis. Am J Kidney Dis. 2005;45:295–302.PubMedCrossRef
98.
Lau KK, Suzuki H, Novak J, et al. Pathogenesis of Henoch-Schönlein purpura nephritis. Pediatr Nephrol. 2010;25:19–26.PubMedCrossRef
99.
Meuwese CL, Carrero JJ, Stenvinkel P. Recent insights in inflammation-associated 95. wasting in patients with chronic kidney disease. Contrib Nephrol. 2011;171:120–6.PubMedCrossRef
100.
Palomar-Fontanet R, Lavin-Gómez BA, Quintanar-Lartundo JA, et al. Markers of inflammation before and during peritoneal dialysis. Adv Perit Dial. 2011;27:28–32.PubMed
Metadaten
Titel
Biology of Human Pentraxin 3 (PTX3) in Acute and Chronic Kidney Disease
verfasst von
Marijn M. Speeckaert
Reinhart Speeckaert
Juan J. Carrero
Raymond Vanholder
Joris R. Delanghe
Publikationsdatum
01.07.2013
Verlag
Springer US
Erschienen in
Journal of Clinical Immunology / Ausgabe 5/2013
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-013-9879-0

Weitere Artikel der Ausgabe 5/2013

Journal of Clinical Immunology 5/2013 Zur Ausgabe

Original Research

Decreases in the Numbers of Peripheral Blood Regulatory T Cells, and Increases in the Levels of Memory and Activated B Cells, in Patients with Active Eosinophilic Granulomatosis and Polyangiitis

Original Research

Serum Levels of Calreticulin in Correlation with Disease Activity in Patients with Rheumatoid Arthritis

Original Research

AIM2 Facilitates the Apoptotic DNA-induced Systemic Lupus Erythematosus via Arbitrating Macrophage Functional Maturation

Original Research

Effect of Hyperoxia on Pulmonary SIgA and Its Components, IgA and SC

Original Research

Interferon Alpha Treatment of Patients with Impaired Interferon Gamma Signaling

Original Research

TNF-α-Secreting B Cells Contribute to Myocardial Fibrosis in Dilated Cardiomyopathy

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise